MicroRNAs as regulators of immune checkpoints in cancer immunotherapy: targeting PD-1/PD-L1 and CTLA-4 pathways
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
MicroRNAs as regulators of immune checkpoints in cancer immunotherapy: targeting PD-1/PD-L1 and CTLA-4 pathways ; volume:24 ; number:1 ; day:10 ; month:3 ; year:2024 ; pages:1-32 ; date:12.2024
Cancer cell international ; 24, Heft 1 (10.3.2024), 1-32, 12.2024
- Creator
-
Zabeti Touchaei, Arefeh
Vahidi, Sogand
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12935-024-03293-6
- URN
-
urn:nbn:de:101:1-2405122113329.238914100890
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:59 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Zabeti Touchaei, Arefeh
- Vahidi, Sogand
- SpringerLink (Online service)
Other Objects (12)
Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer
Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer
Inhibitors of immune checkpoints—PD-1, PD-L1, CTLA-4—new opportunities for cancer patients and a new challenge for internists and general practitioners
Small molecule inhibitors against PD-1/PD-L1 immune checkpoints and current methodologies for their development: a review
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
The CTLA ‐4 immune checkpoint protein regulates PD‐L1: PD ‐1 interaction via transendocytosis of its ligand CD80
Expression of PD-L1, CTLA-4, and LAG-3 in human thyroid carcinoma
Neoadjuvant PD-1/PD-L1 combined with CTLA-4 inhibitors for solid malignancies: a systematic review and meta-analysis
Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases
Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases
Comparative Analysis of Inhibitory and Activating Immune Checkpoints PD-1, PD-L1, CD28, and CD86 in Non-Melanoma Skin Cancer
Regulatory mechanisms of PD-1/PD-L1 in cancers
Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer
Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer
Inhibitors of immune checkpoints—PD-1, PD-L1, CTLA-4—new opportunities for cancer patients and a new challenge for internists and general practitioners
Small molecule inhibitors against PD-1/PD-L1 immune checkpoints and current methodologies for their development: a review
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
The CTLA ‐4 immune checkpoint protein regulates PD‐L1: PD ‐1 interaction via transendocytosis of its ligand CD80
Expression of PD-L1, CTLA-4, and LAG-3 in human thyroid carcinoma
Neoadjuvant PD-1/PD-L1 combined with CTLA-4 inhibitors for solid malignancies: a systematic review and meta-analysis
Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases
Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases
Comparative Analysis of Inhibitory and Activating Immune Checkpoints PD-1, PD-L1, CD28, and CD86 in Non-Melanoma Skin Cancer
Regulatory mechanisms of PD-1/PD-L1 in cancers
Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer
Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer
Inhibitors of immune checkpoints—PD-1, PD-L1, CTLA-4—new opportunities for cancer patients and a new challenge for internists and general practitioners
Small molecule inhibitors against PD-1/PD-L1 immune checkpoints and current methodologies for their development: a review
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
The CTLA ‐4 immune checkpoint protein regulates PD‐L1: PD ‐1 interaction via transendocytosis of its ligand CD80
Expression of PD-L1, CTLA-4, and LAG-3 in human thyroid carcinoma
Neoadjuvant PD-1/PD-L1 combined with CTLA-4 inhibitors for solid malignancies: a systematic review and meta-analysis
Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases
Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases
Comparative Analysis of Inhibitory and Activating Immune Checkpoints PD-1, PD-L1, CD28, and CD86 in Non-Melanoma Skin Cancer